TiumBio Information

View Top Employees from TiumBio

TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Our mission is to enhance the hope and happiness of humanity through scientific advancements. TiumBio currently has three leading pipeline assets in clinical trials, with TU2218 being investigated in Phase 2 and TU2670 and TU7710 in Phase 1. TU2218 is an oral immuno-oncology therapy targeting TGF-beta and VEGFR2, while TU2670 is an orally active non-peptide GnRH antagonist. Additionally, TU7710 is a bypass-factor treatment specifically designed for hemophilia patients who have developed neutralizing antibodies. TiumBio is located in Seongnam-si, South Korea and has three subsidiaries including Boston-based biotechnology company, Initium Therapeutics and a CDO compnay, Protium Science. For any media inquiry or investor relations, contact ir@tiumbio.com

Website	http://www.tiumbio.com/en/
Revenue	$5.6 million
Employees	14 (10 on RocketReach)
Founded	2016
Address	6F, Pangyo IT Center, 30 Changup-ro 40 beon-gil, Sujeong-gu, Seongnam-si, Gyeonggi-do 13449, KR
Phone	+81 3-1600-1500
Industry	Biotechnology Research, Drug Stores & Pharmacies, Health Care, Drug Discovery, Retail, Medical
Keywords	Biopharmaceutical, Rare Diseases, Incurable Diseases, Clinical Stage, Drug Discovery, Therapeutic Development, Innovative Therapeutics, Biotechnology, Pharmaceutical Research, Clinical Trials, New Treatments, Orphan Drugs, Patient Care, Health Care, Medical Research, Disease Treatment, Drug Development, Life Sciences, Pharmaceutical, Biotech
Competitors	Roche, Thermo Fisher Scientific, Abbott, Merck Group, Agilent Technologies, Illumina, PerkinElmer, Inc., Bio-Rad Laboratories, QIAGEN, Celerion +41 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies